Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

C ANDREW SCHROEDER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1386755346
CMS profile
62231
Location
BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$73,998.49

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $73,605.31 78
AstraZeneca Pharmaceuticals LP $236.72 9
IDORSIA PHARMACEUTICALS US INC $32.98 2
Mallinckrodt Hospital Products Inc. $32.67 1
Lilly USA, LLC $28.62 1
Mylan Specialty L.P. $23.14 1
AbbVie Inc. $23.03 1
Amgen Inc. $16.02 1

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

C ANDREW SCHROEDER

NPI 1386755346 · CMS profile ID 62231

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386755346?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
C ANDREW SCHROEDER, NPI 1386755346, CMS profile ID 62231. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386755346?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). C ANDREW SCHROEDER, NPI 1386755346, CMS profile ID 62231. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386755346?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
C ANDREW SCHROEDER, NPI 1386755346, CMS profile ID 62231, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1386755346?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $73,998.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–94 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.0203/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019846543 CMS
GlaxoSmithKline, LLC. $25.9203/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506421 CMS
GlaxoSmithKline, LLC. $44.1103/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506445 CMS
GlaxoSmithKline, LLC. $282.1203/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506603 CMS
GlaxoSmithKline, LLC. $156.7203/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508581 CMS
GlaxoSmithKline, LLC. $350.0003/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002510483 CMS
AbbVie Inc. $23.0303/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998874613 CMS
GlaxoSmithKline, LLC. $3,900.0003/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504581 CMS
GlaxoSmithKline, LLC. $27.2503/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506591 CMS
GlaxoSmithKline, LLC. $3,900.0003/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508635 CMS
GlaxoSmithKline, LLC. $69.6903/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506571 CMS
GlaxoSmithKline, LLC. $397.8003/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504523 CMS
GlaxoSmithKline, LLC. $10.0003/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506390 CMS
GlaxoSmithKline, LLC. $3,900.0003/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504501 CMS
GlaxoSmithKline, LLC. $650.0003/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508615 CMS
GlaxoSmithKline, LLC. $14.6403/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508451 CMS
GlaxoSmithKline, LLC. $292.9103/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508519 CMS
GlaxoSmithKline, LLC. $57.2003/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508693 CMS
GlaxoSmithKline, LLC. $121.8703/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504605 CMS
GlaxoSmithKline, LLC. $226.1703/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504639 CMS
GlaxoSmithKline, LLC. $10.0003/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508463 CMS
GlaxoSmithKline, LLC. $228.7903/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508603 CMS
GlaxoSmithKline, LLC. $427.9603/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002510391 CMS
GlaxoSmithKline, LLC. $326.0003/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002510494 CMS
AstraZeneca Pharmaceuticals LP $20.9902/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015173859 CMS
GlaxoSmithKline, LLC. $124.7202/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002510423 CMS
GlaxoSmithKline, LLC. $975.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508551 CMS
GlaxoSmithKline, LLC. $114.8902/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508671 CMS
GlaxoSmithKline, LLC. $1,300.0002/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506549 CMS
GlaxoSmithKline, LLC. $3,900.0002/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506561 CMS
GlaxoSmithKline, LLC. $3,900.0002/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506615 CMS
GlaxoSmithKline, LLC. $3,900.0002/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508593 CMS
GlaxoSmithKline, LLC. $1,300.0002/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504489 CMS
GlaxoSmithKline, LLC. $1,300.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506501 CMS
GlaxoSmithKline, LLC. $123.9501/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506433 CMS
GlaxoSmithKline, LLC. $121.8801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002506413 CMS
GlaxoSmithKline, LLC. $328.3001/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504513 CMS
GlaxoSmithKline, LLC. $178.3701/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504593 CMS
GlaxoSmithKline, LLC. $124.4001/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002504647 CMS
GlaxoSmithKline, LLC. $8.0001/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002508483 CMS
GlaxoSmithKline, LLC. $163.9001/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002510411 CMS
AstraZeneca Pharmaceuticals LP $24.4501/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011775971 CMS
AstraZeneca Pharmaceuticals LP $21.2801/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011811679 CMS
AstraZeneca Pharmaceuticals LP $41.6401/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011479299 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,707.26 91
PY2020 $14,879.69 50
PY2021 $48,240.03 43
PY2022 $100,317.31 95
PY2023 $73,998.49 94
PY2024 $18,891.98 45
PY2025 $1,202.75 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $17,361.00 16
PY2024 Principal investigator $39,816.50 9
PY2023 Principal investigator $60,008.75 11
PY2022 Principal investigator $26,515.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 12/02/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121144
Principal investigator 1 GlaxoSmithKline, LLC. $211.00 11/24/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192136405
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 11/04/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121125
Principal investigator 1 GlaxoSmithKline, LLC. $211.00 10/15/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192140807
Principal investigator 1 GlaxoSmithKline, LLC. $211.00 09/17/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192140813
Principal investigator 1 SANOFI US SERVICES INC. $450.00 09/15/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121081
Principal investigator 1 GlaxoSmithKline, LLC. $211.00 08/21/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192136398
Principal investigator 1 GlaxoSmithKline, LLC. $422.00 07/25/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192140824
Principal investigator 1 GlaxoSmithKline, LLC. $4,042.00 06/06/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192136392
Principal investigator 1 SANOFI US SERVICES INC. $1,450.00 05/27/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121016
Principal investigator 1 GlaxoSmithKline, LLC. $483.00 05/14/2025 Non-covered Recipient Entity
MACRO TRIALS INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192140819
Principal investigator 1 SANOFI US SERVICES INC. $150.00 04/21/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120989
Principal investigator 1 SANOFI US SERVICES INC. $2,520.00 04/14/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120999
Principal investigator 1 SANOFI US SERVICES INC. $300.00 04/14/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226121003
Principal investigator 1 SANOFI US SERVICES INC. $300.00 02/10/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120962
Principal investigator 1 SANOFI US SERVICES INC. $3,900.00 01/21/2025 Non-covered Recipient Entity
Macro Trials Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120959